Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors

Eun Jig Lee, Tom J. Kotlar, Ivan Ciric, Mi Kyung Lee, Sung Kil Lim, Hyun Chul Lee, Kap Bum Huh, Kelly E. Mayo, J. Larry Jameson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The molecular events leading to the development of GH-producing pituitary tumors remain largely unknown. We hypothesized that activating mutations of the GHRH receptor might occur in a subset of GH-producing pituitary tumors. Genomic DNA samples from 54 GH-producing pituitary tumor tissues were screened for mutations of the GHRH receptor. Eleven homozygous or heterozygous nucleotide substitutions [169G > A (A57T), 338C > T (P113L), 363G > T (E121D), 409C > T (H137Y), 547G > A (D183N), 673G > A (V225I), 749G > A (W250X), 760G > A (V254M), 785G > A (S262N), 880G > A (G294R), 1268G > A (C423Y)] were found in 12 patients (22.2%). The 169G > A substitution (A57T) appears to be a polymorphism (4 patients, 7.4%). E121D and V225I were each found in 2 patients. In 1 patient with the V225I sequence, the substitution was not found in genomic DNA from peripheral leukocytes, suggesting a somatic mutation. A patient with a heterozygous W250X mutation was homozygous for the C423Y substitution. These variant GHRH receptors were studied in transfected TSA-201 cells to evaluate the functional consequences of the amino acid changes. None of the GHRH receptor variants was associated with basal elevation of intracellular cAMP. GHRH induced variable cAMP responses. With the W250X and G294R variants, there was no cAMP stimulation by GHRH, indicating that the mutations are inactivating. Expression of the W250X GHRH receptor on the cell membrane was severely decreased and GHRH binding to the G294R GHRH receptor was impaired. Although GHRH receptor variants are common in GH-producing pituitary adenomas, constitutively activating mutations, as a mechanism for GH-producing pituitary tumors appear to be rare.

Original languageEnglish
Pages (from-to)3989-3995
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume86
Issue number8
DOIs
Publication statusPublished - 2001 Jan 1

Fingerprint

Pituitary Neoplasms
Tumors
Mutation
Substitution reactions
DNA
Cell membranes
somatotropin releasing hormone receptor
Polymorphism
Leukocytes
Nucleotides
Cell Membrane
Tissue
Amino Acids

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Lee, Eun Jig ; Kotlar, Tom J. ; Ciric, Ivan ; Lee, Mi Kyung ; Lim, Sung Kil ; Lee, Hyun Chul ; Huh, Kap Bum ; Mayo, Kelly E. ; Jameson, J. Larry. / Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. In: Journal of Clinical Endocrinology and Metabolism. 2001 ; Vol. 86, No. 8. pp. 3989-3995.
@article{58053e1cdeea4c8da2066f5756fe4fa4,
title = "Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors",
abstract = "The molecular events leading to the development of GH-producing pituitary tumors remain largely unknown. We hypothesized that activating mutations of the GHRH receptor might occur in a subset of GH-producing pituitary tumors. Genomic DNA samples from 54 GH-producing pituitary tumor tissues were screened for mutations of the GHRH receptor. Eleven homozygous or heterozygous nucleotide substitutions [169G > A (A57T), 338C > T (P113L), 363G > T (E121D), 409C > T (H137Y), 547G > A (D183N), 673G > A (V225I), 749G > A (W250X), 760G > A (V254M), 785G > A (S262N), 880G > A (G294R), 1268G > A (C423Y)] were found in 12 patients (22.2{\%}). The 169G > A substitution (A57T) appears to be a polymorphism (4 patients, 7.4{\%}). E121D and V225I were each found in 2 patients. In 1 patient with the V225I sequence, the substitution was not found in genomic DNA from peripheral leukocytes, suggesting a somatic mutation. A patient with a heterozygous W250X mutation was homozygous for the C423Y substitution. These variant GHRH receptors were studied in transfected TSA-201 cells to evaluate the functional consequences of the amino acid changes. None of the GHRH receptor variants was associated with basal elevation of intracellular cAMP. GHRH induced variable cAMP responses. With the W250X and G294R variants, there was no cAMP stimulation by GHRH, indicating that the mutations are inactivating. Expression of the W250X GHRH receptor on the cell membrane was severely decreased and GHRH binding to the G294R GHRH receptor was impaired. Although GHRH receptor variants are common in GH-producing pituitary adenomas, constitutively activating mutations, as a mechanism for GH-producing pituitary tumors appear to be rare.",
author = "Lee, {Eun Jig} and Kotlar, {Tom J.} and Ivan Ciric and Lee, {Mi Kyung} and Lim, {Sung Kil} and Lee, {Hyun Chul} and Huh, {Kap Bum} and Mayo, {Kelly E.} and Jameson, {J. Larry}",
year = "2001",
month = "1",
day = "1",
doi = "10.1210/jcem.86.8.7732",
language = "English",
volume = "86",
pages = "3989--3995",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. / Lee, Eun Jig; Kotlar, Tom J.; Ciric, Ivan; Lee, Mi Kyung; Lim, Sung Kil; Lee, Hyun Chul; Huh, Kap Bum; Mayo, Kelly E.; Jameson, J. Larry.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 8, 01.01.2001, p. 3989-3995.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors

AU - Lee, Eun Jig

AU - Kotlar, Tom J.

AU - Ciric, Ivan

AU - Lee, Mi Kyung

AU - Lim, Sung Kil

AU - Lee, Hyun Chul

AU - Huh, Kap Bum

AU - Mayo, Kelly E.

AU - Jameson, J. Larry

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The molecular events leading to the development of GH-producing pituitary tumors remain largely unknown. We hypothesized that activating mutations of the GHRH receptor might occur in a subset of GH-producing pituitary tumors. Genomic DNA samples from 54 GH-producing pituitary tumor tissues were screened for mutations of the GHRH receptor. Eleven homozygous or heterozygous nucleotide substitutions [169G > A (A57T), 338C > T (P113L), 363G > T (E121D), 409C > T (H137Y), 547G > A (D183N), 673G > A (V225I), 749G > A (W250X), 760G > A (V254M), 785G > A (S262N), 880G > A (G294R), 1268G > A (C423Y)] were found in 12 patients (22.2%). The 169G > A substitution (A57T) appears to be a polymorphism (4 patients, 7.4%). E121D and V225I were each found in 2 patients. In 1 patient with the V225I sequence, the substitution was not found in genomic DNA from peripheral leukocytes, suggesting a somatic mutation. A patient with a heterozygous W250X mutation was homozygous for the C423Y substitution. These variant GHRH receptors were studied in transfected TSA-201 cells to evaluate the functional consequences of the amino acid changes. None of the GHRH receptor variants was associated with basal elevation of intracellular cAMP. GHRH induced variable cAMP responses. With the W250X and G294R variants, there was no cAMP stimulation by GHRH, indicating that the mutations are inactivating. Expression of the W250X GHRH receptor on the cell membrane was severely decreased and GHRH binding to the G294R GHRH receptor was impaired. Although GHRH receptor variants are common in GH-producing pituitary adenomas, constitutively activating mutations, as a mechanism for GH-producing pituitary tumors appear to be rare.

AB - The molecular events leading to the development of GH-producing pituitary tumors remain largely unknown. We hypothesized that activating mutations of the GHRH receptor might occur in a subset of GH-producing pituitary tumors. Genomic DNA samples from 54 GH-producing pituitary tumor tissues were screened for mutations of the GHRH receptor. Eleven homozygous or heterozygous nucleotide substitutions [169G > A (A57T), 338C > T (P113L), 363G > T (E121D), 409C > T (H137Y), 547G > A (D183N), 673G > A (V225I), 749G > A (W250X), 760G > A (V254M), 785G > A (S262N), 880G > A (G294R), 1268G > A (C423Y)] were found in 12 patients (22.2%). The 169G > A substitution (A57T) appears to be a polymorphism (4 patients, 7.4%). E121D and V225I were each found in 2 patients. In 1 patient with the V225I sequence, the substitution was not found in genomic DNA from peripheral leukocytes, suggesting a somatic mutation. A patient with a heterozygous W250X mutation was homozygous for the C423Y substitution. These variant GHRH receptors were studied in transfected TSA-201 cells to evaluate the functional consequences of the amino acid changes. None of the GHRH receptor variants was associated with basal elevation of intracellular cAMP. GHRH induced variable cAMP responses. With the W250X and G294R variants, there was no cAMP stimulation by GHRH, indicating that the mutations are inactivating. Expression of the W250X GHRH receptor on the cell membrane was severely decreased and GHRH binding to the G294R GHRH receptor was impaired. Although GHRH receptor variants are common in GH-producing pituitary adenomas, constitutively activating mutations, as a mechanism for GH-producing pituitary tumors appear to be rare.

UR - http://www.scopus.com/inward/record.url?scp=0034891694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034891694&partnerID=8YFLogxK

U2 - 10.1210/jcem.86.8.7732

DO - 10.1210/jcem.86.8.7732

M3 - Article

C2 - 11502843

AN - SCOPUS:0034891694

VL - 86

SP - 3989

EP - 3995

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -